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Aldose reductase, a key enzyme of the polyol pathway catalyses NADPH-dependent reduction of glucose to 
sorbitol. Increased activity of this enzyme is considered a major factor contributing to the development of 
diabetic complications hence could be an important target in the treatment of these complications. In this 
work, a database of sesquiterpenes was prepared and screened for their drug-like properties based on the 
Lipinski’s rule of 5. The co-crystallised structure of aldose reductase was obtained from the Protein Data 
bank and prepared for docking. In silico docking experiments was performed on Autodock tools using 198 
sesquiterpene lactones that passed screening, and compounds with the lowest binding energy and 
favourable binding interactions were selected for molecular docking simulation. Six of the best ranking 
compounds selected had binding energies ranging from–11.96 Kcal/mol to -9.45 Kcal/mol and were 
comparable to the energy of the standard inhibitor Idd594 used in the study. They also show good 
complementarity in their binding to the residues of the binding pocket. The results suggest that 
dehydrooopodin (1), 11(S),13-dihydrolactucopicrin (2), and Chrysanin (3) offered potential inhibitory 
activities toward aldose reductase and may serve as lead compounds for in vivo validation as aldose 
reductase inhibitors. 
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INTRODUCTION 
Diabetes mellitus (DM) is a group of endocrine 
metabolic dysfunctions characterized by an 
abnormal increase in blood glucose levels 
resulting from inadequate insulin production, 
decreased insulin sensitivity and function, or 
excessive glucagon secretion (Blair, 2016; Tan et 
al., 2019). The global burden of diabetes mellitus 
is very high and is increasing rapidly. According 
to the International Diabetic Federation (IDF), it is 
estimated that 451 million people were living with 
diabetes in 2017 and the prevalence is expected 
to reach 693 million by 2045 (IDF, 2017). 
Diabetes is responsible for an estimated global 
economic expense costing about US$727 billion 
of the total global adult health expenditure in 
2017 (Afroz et al., 2019), and a projected 
increased is expected to be US$776 billion by 
2045 (IDF, 2017). 
 
The most devastating effect of chronic DM is the 
gradual progressive damage of vascular 
endothelial cells, which result in diabetic 
complications (Georgescu, 2011). Retinopathy, 
among the chronic complications of diabetes, is 
the leading cause of blindness (Garofolo et al., 
2019; Hippisley-Cox and Coupland, 2016). 
Evidence from biochemical studies has shown 
that the polyol pathway plays a major role in the 
development of retinopathy (Oates, 2008; Tang 
et al., 2012). Aldose reductase (AR2, EC1.1.1.21) 
is the first enzyme of the polyol pathway. It 
catalyses the reduction of glucose to sorbitol with 
concomitant oxidation of NADPH to NADP+. 
Increased activity of this enzyme causes 
accumulation of sorbitol leading to osmotic 
stress.  In addition, the depletion of NADPH 
causes alterations in cellular redox potentials and 
reduced activity of enzymes such as nitric oxide 
synthase (NOS) and glutathione reductase which 
leads to cellular oxidative stress (Forbes and 
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Cooper, 2013). The osmotic and oxidative stress 
contribute to cellular damage through the 
activation of extracellular signal transduction 
cascade and subsequent expression of 
inflammatory cytokines (Kashihara et al., 2010; 
Tang et al., 2012; Zehra and Zarina, 2012).  
 
Aldose reductase has been targeted for the 
treatment of diabetic complications. Inhibitors of 
this enzyme have been shown to delay the onset 
and slow the progression to chronic diabetic 
complications in experimental animal models 
(Chung and Chung, 2005). Unfortunately, most of 
the aldose reductase inhibitors (ARIs) developed 
over the past three decades fail to pass the 
phase III clinical trials either due to toxicity or 
pharmacokinetic problems (Chung and Chung, 
2005).  At present, only one aldose reductase 
inhibitor-Epalrestat is commercially available 
(Sato et al., 2014). Hence, there is need for 
further research into newer ARIs. Molecular 
docking techniques have been used to study 
molecules that are likely to bind to a drug target 
in silico. The autodock suite is one of several 
softwares that has been developed for automated 
docking programs designed to predict how small 
molecules bind to 3D structures of target 
receptors. Besides calculating the binding 
energies, Autodock tools have graphical user 
interphase (GUI) that can be used to visualize the 
binding mode of the ligands, which is very useful 
in drug design. This technique is explored in this 
study to characterize sesquiterpene lactones 
group of secondary metabolites commonly found 
in plants belonging to the family, Astraceae 
(Ivanescu et al., 2015) for their possible inhibitory 
effects on aldose reductase enzyme in silico. 
 
MATERIALS AND METHODS 
Software and Programs 
The virtual screening of sesquiterpene lactones 
was carried out in a Linux cluster system in 
Pharmaceutical Design and Simulation 
laboratory, Universiti Sains Malaysia. The 
programs that were used include Python 2.5 
available at www.python.com, Molecular 
Graphics library MGLTools1.5.6, AutodockTools 
4.2 (for in silico docking experiments), and 
Racconautodock available at www.scripps.edu.  
Other programs used include Discovery Studio 
2.2.5, Marvinsketch (Chemaxon), and Microsoft 
Excel (version, 2013). 
 
Preparation of Ligand Database 
A ligand database of 208 sesquiterpene lactones 
was obtained from Pubchem, Chemspider and 
Zinc databases and saved in sdf format. Few of 
the compounds obtained from literature and their 
chemical structures were built using the 
Marvinsketch (http://www.chemaxon.com/my-
chemaxon/my-academic-license/). The prepared 
ligand program Discovery studio 2.5.5 (Accelrys 
Software Inc.) was used for geometry 
optimization and subsequent screening of the 
ligands based on Lipinski’s rule (Christiphor et al., 
2019). A total of 198 ligands that passed the 
Lipinski’s rule were converted to pdbqt file format 
using a Raccoon Autodock program (Forli et al., 
2016) and saved for virtual screening. 
 
Aldose Reductase Docking Simulation 
Studies 
A high-resolution X-ray diffraction structure of 
human aldose reductase in complex with known 
inhibitor Idd594 (PDB code: 1US0) was retrieved 
from Protein Data Bank. The macromolecule was 
prepared using Autodock 4.2 (Morris et al., 2009). 
Ligand and water molecules were removed, all 
hydrogens were added, and Gasteiger charges 
were calculated for each of the molecules. The 
prepared macromolecules were saved in pdbqt 
format. To ensure the correct conformation of 
ligand binding to active sites during virtual 
screening, a grid parameter file (GPF) was 
generated for the receptor and its co-crystallised 
ligand by identifying Coordinates of Central Grid 
Point of Maps (GridBox). Subsequently, docking 
validation was performed by re-docking the co-
crystallized ligands Idd594 on binding sites of the 
aldose reductase receptor. The rotational bonds 
of the ligands were treated as flexible, while 
those of the protein were kept rigid. Grid boxes 
were fixed around the NADPH -binding site using 
the ligand as the grid box centre. The box size 
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was set to 50, 50, and 60 Å3 (x, y, and z, 
respectively) and the grid spacing to 0.375Å. The 
grid maps for atom were calculated for each 
ligand types for each of the three ligands. Genetic 
Algorithm (GA) was used for searching, and the 
population size was set to 150, 100 runs, and 5 
million energy evaluations. The grid and docking 
parameters were then computed for all ligands 
using parameters obtained from the re-docking of 
co-crystallized ligands as reference. The 
intermolecular interactions were computed as 
free binding energies as follows: 
Free Binding Energy = P + Q +R –S (Huey et al., 
2007) 
where, P represents final intermolecular energy + 
van der Walls energy (vdW) + hydrogen bonds + 
desolvation energy + electrostatic energy 
(kcal/mol); Q represents final total internal energy 
(kcal/mol); R represents torsional free energy 




Table 1 shows zero Lipinski rule violations for six 
selected compounds: dehydrooopodin (1), 
11(S),13-dihydrolactucopicrin (2), Chrysanin (3), 
Subcordatolide C (4), Budlein A (5), and 
Vernodalin (6), which is an indication of 
favourable bioavailability of selected molecules 
(Figure 1).  
 
Table 1: Properties of compounds selected top ranked compounds 
Compounds Mw nHBA nHBD LogP PSA(Å2) 
1 328.4 2 0 4.21 56.60 
2 412.4 5 2 1.81 110.13 
3 356.5 3 1 2.28 72.83 
4 334.4 3 1 2.75 72.83 
5 372.4 5 1 1.88 99.13 
6 360.7 4 1 1.60 99.13 
Mw = molecular weight, nHBA = number of hydrogen bond, nHBD = nunber of hydrogen 
bond donors, PSA = polar suface area 
 
 
Figure 1: Chemical structure of selected compounds 1-6.  





The amino acid sequence Trp20, Val 47 Tyr48, 
Trp79, His 110, Trp111, Phe122 Trp219, Cys298, 
Ala299, and Leu300 were defined in the binding 
site of the crystallized ligand Idd594 (Figure 2A 
and B). The active site comprised two different 
pockets, the catalytic pocket, and specificity 
pocket (Figure 2A). The catalytic pocket is deeply 
buried and is composed of polar residues (Tyr48, 
Lys77, His110, Trp111), nicotinamide moiety of 
the co-factor NADPH, and the other hydrophobic 
residues constitute the specificity pocket. The re-
docking of reference ligand (Idd594) into the 
active site of ALR2 occupies the same binding 
pocket at root mean square deviation (RMSD) of 
0.88A, which further validates the present 













Figure 2: Active site of ALR2 - (A) Surface structure of the active site with 1dd594. Ligand is shown 
in green, hydrophobic sub-pocket in brown and anionic sub-pocket region in blue. (B) Crystal pose 
of idd594 interacting with amino acid residues. Ligand is shown in magenta colour, Hydrogen bonds 
in green dotted lines. 
 
Table 2 shows the ranking of the molecular 
binding energies of compounds 1 – 6 which 
range from -11.5 kcal/mole to -9.45 kcal/mol.  
The compound with the lowest energy is 
expected to have the highest inhibition constant. 
Compounds 1-3 have lower binding energies 
when compared with the standard ligand idd594 
(-10.55 kcal/mol) which suggest better inhibition 
constant while compounds 4-6 have lesser 
binding affinity than the co-crystallized reference 
ligand. This is an indication that the selected 
compounds demonstrate a good binding affinity 
for ALR2.  
 
Figure 3 (A-E) shows the binding poses of the six 
compounds with the amino acid residues of the 
ALR2 active site. In docking pose of compound 1 
(Figure 3A), the ester group of the acrylate side 
chain is positioned in the catalytic pocket were 
the carbonyl oxygen form hydrogen bonding with 
Tyr48, His110, and Trp111, the other ring portion 
form hydrophobic interaction with non-polar 
residues. The carbonyl oxygen of the γ-lactone 
ring form additional H-bonding with backbone 
oxygen of Leu300 and Ala299. Compounds 2 – 6 
display a common binding pattern, different from 
the binding mode seen in 1 (Figure 3B-F). The 
carbonyl group of the γ-lactone of these 
compounds is positioned in the catalytic pocket 
where it exhibits hydrogen bonding with polar 
Tyr48, His110, and/or Trp111. The other cyclic 
portion and side-chain form hydrophobic 
interactions with non-polar residues. 
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1 -11.96 Tyr48, His110, 
Leu 300 
Trp20, Trp111, Trp219, Cys 
298, Leu300 
8 
 -10.57 Try48, His110 Trp79, Trp111, Cys298, 
Leu300, Cys303 
7 
3 -10.56 Try48, His110 Trp20, Val47,  Trp111, 
Trp219, Cys 298, Leu300 
8 
4 -9.97 Try48, His110, 
Trp111 
Trp20, Val47,  Trp219, Cys 
298 
7 
5 -9.88 Tyr48, His110, 
Trp111 
Trp20, Cys 298 5 
6 -9.45 Tyr48, His 110, 
Ala 299 






-10.55 Tyr48, His110, 
Cys 298, Thr113 
None 4 
 
   
 
 Figure 3: Docking poses of ligands interactions with amino acid residues. A – F poses of 
compounds 1 – 6, respectively. Ligands are shown in grey colour, hydrogen bond in green 
dotted lines, hydrophobic interactions in purple dotted lines. 




The amino acid sequence Trp20, Val Tyr48, 
Trp79, His 110, Trp111, Phe122 Trp219, Cys298, 
Ala299, and Leu300 that defines the active site of 
aldose reductase formed an intermolecular 
interaction with the sesquiterpene lactones. As a 
general rule, hydrogen bond interaction with the 
Tyr48, His110, and Trp111 in the catalytic pocket 
and hydrophobic interactions with polar residues 
of the specificity pocket have been found to be 
responsible for mediating the aldose reductase 
inhibition (El-Kabbani et al., 2004; Howard et al., 
2004). The binding modes for selected ligands 
were inspected and each ligand selected based 
on the criteria that it must exhibit hydrogen 
bonding with at least two of the residue Tyr48, 
His110 and Trp111, and must have hydrophobic 
interaction with relevant residues in the specificity 
pockets (Trp20, Trp111, Cys298, Ala299, and 
Leu300). This suggests that compounds 1 – 6 
demonstrate the potential to bind and inhibit the 
catalytic ability of ALR2. 
 
The binding of the lactone group of sesquiterpene 
lactones into the catalytic pocket of aldose 
reductase observed in the present study has 
been similarly observed in the findings of Wang 
et al. (2008) where they observed coumarin 
lactone ring act as an acceptor to build the 
hydrogen bond network with the polar residues of 
the catalytic pocket of aldose reductase. Another 
study by Wang et al. (2009) showed the binding 
of the lactone ring of a group of phenolic marine 
compounds into the catalytic pocket of aldose 
reductase displayed high stability during the 
molecular dynamics studies. The central lactone 
ring was also shown to exhibit similar binding 
mode as revealed in this study. This is an 
indication that the lactone could serve as an 
alternative functional group to cyclic imide and 
carboxylic acid in the development of newer 
aldose reductase inhibitors.  
 
CONCLUSION 
Based on the docking study, the selected 
sesquiterpene lactones were found to have 
binding energies that stabilize their interaction 
with the target enzyme. Specifically, compounds 
1, 2, and 3 had lower binding energies than the 
standard aldose reductase inhibitor (Idd594). 
Findings from the present study suggest that the 
selected sesquiterpene lactones offer a potential 
inhibitory activity towards aldose reductase 
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